The isolation and characterization of Escherichia coli O157:H7 strains from 22 out of 174 fecal samples from petting zoo animals representing twenty‐two different species (camel, lion, goats, zebra, bear, baboon monkey, Siberian monkey, deer, elk, llama, pony, horses, fox, kangaroo, wolf, porcupine, chickens, tiger, ostrich, hyena, dogs, and wildcats) were investigated. One petting Al‐Zawraa zoological society of Baghdad was investigated for E. coli O157:H7 over a 16‐month period that spanned two summer and two autumn seasons. Variation in the occurrence of E. coli O157:H7‐positive petting zoo animals was observed, with animals being culture pos

Visceral leishmaniasis is a neglected tropical disease on the rise in different regions of Iraq, especially in areas with poor hygiene and among refugee populations. The effectiveness of existing chemotherapy for leishmaniasis is constrained by its high toxicity, cost, and the development of drug resistance. The current research examined various concentrations (ranging from 125 to 1000 μM) of lupeol to evaluate its ability to boost the generation of nitric oxide, which has anti-leishmanial properties, in an ex-vivo macrophage model. Griess assay was used to detect the nitric oxide (NO) production in Leishmania donovani infected U937 cell-line macrophages along 24 and 48 hours post treated. The nitric oxide concentration was signifi

Introduction:Visceral leishmaniasis (VL), also known as kala-azar, is a diffuse protozoan infection caused by Leishmania donovani complex. VL is principally caused by L. donovani and L. infantum (synonym L. chagasi in South America). The parasite targets the reticulo-endothelial system, with penetration of the spleen, liver, bone marrow and lymph nodes lead to organomegaly and pancytopenia. Organic pentavalent antimonials have been the first-line drugs for the therapy of leishmaniasis for the latest six decades, and clinical resistance to these drugs has emerged as a primary obstacle to successful treatment and control. Miltefosine has been shown to be higher or equivalent to presently approved essential medicines for at least one of viscer